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Abstract  1 
Background: pyoderma gangrenosum (PG) is an uncommon dermatosis with a limited evidence base for 2 
treatment. 3 
Objective: to estimate the effectiveness of topical therapies in the treatment of PG. 4 
Methods:  prospective cohort study of UK secondary care patients with a clinical diagnosis of PG suitable for 5 
topical treatment (recruited July 2009 to June 2012). Participants received topical therapy following normal 6 
clinical practice (mainly Class I-III topical corticosteroids, tacrolimus 0.03% or 0.1%).  Primary outcome: speed 7 
of healing at 6 weeks. Secondary outcomes: proportion healed by 6 months; time to healing; global 8 
assessment; inflammation; pain; quality-of-life; treatment failure and recurrence. 9 
Results: Sixty-six patients (22 to 85 years) were enrolled. Clobetasol propionate 0.05% was the most commonly 10 
prescribed therapy. Overall, 28/66 (43.8%) of ulcers healed by 6 months. Median time-to-healing was 145 days 11 
(95% CI: 96 days, ∞). Initial ulcer size was a significant predictor of time-to-healing (hazard ratio 0.94 (0.88; 12 
1.00); p = 0.043). Four patients (15%) had a recurrence. 13 
Limitations: No randomised comparator 14 
Conclusion: Topical therapy is potentially an effective first-line treatment for PG that avoids possible side-15 
effects associated with systemic therapy. It remains unclear whether more severe disease will respond 16 
adequately to topical therapy alone. 17 
 18 
Key words: pyoderma gangrenosum, topical therapy, corticosteroid, tacrolimus, side-effects, cohort 19 
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Abbreviations 21 
Pyoderma Gangrenosum (PG) 22 
Randomised controlled trial (RCT) 23 
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Introduction 28 
Pyoderma Gangrenosum (PG) is an uncommon, painful ulcerative inflammatory dermatosis that is associated 29 
with considerable morbidity1, 2 and a reported three-fold increased risk of death3. 30 
The most commonly prescribed treatments for PG are systemic therapies (e.g. prednisolone, ciclosporin, 31 
intravenous immunoglobulin or biologic therapies). Nevertheless, topical treatments (e.g. corticosteroids and 32 
calcineurin inhibitors) have also been recommended for localised disease4, 5 and may be a useful first-line 33 
therapy for some patients. 34 
We conducted a multi-centre prospective cohort study to investigate the efficacy of topical therapy as a first-35 
line treatment for PG.  This cohort study was conducted alongside a randomised controlled trial (RCT) of 36 
systemic treatments for PG (STOP GAP Trial), in which oral prednisolone was compared to ciclosporin.6 37 
Our objective was to provide prospectively collected estimates of treatment response for patients receiving 38 
topical therapy for their PG.  39 
Methods 40 
Ethics and regulatory approvals were obtained; participants gave written informed consent. Independent Trial 41 
Steering Committee and Data Monitoring Committees provided oversight. 42 
Study design 43 
Prospective cohort study of patients with a clinical diagnosis of PG, for whom topical therapy was indicated. 44 
Patients with more severe PG (requiring systemic therapy) were enrolled into the parallel RCT6 but were 45 
eligible for inclusion in the topical therapy cohort study if systemic therapy was contra-indicated, or if patient 46 
preference was to receive topical treatment. 47 
Participants were enrolled for up to 6 months, or until the target PG ulcer had healed. Medications were 48 
prescribed as per local practice at the recruiting hospital.  49 
Research questions 50 
1. What is the typical treatment response in patients for whom topical therapy is indicated? 51 
2. What proportion of participants require escalation of treatment to systemic medication? 52 
3. What is the impact of PG on patient-reported quality of life? 53 
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4. What factors predict treatment response? 54 
Participants 55 
Recruitment took place in 28 secondary care hospitals throughout the UK.  Participants were identified from 56 
dermatology, rheumatology, gastroenterology and general medicine clinics. 57 
Participants were aged 18 years or older and had a clinical diagnosis of PG (confirmed by the recruiting 58 
dermatologist, with biopsy to exclude alternative aetiologies if clinically indicated), and at least one 59 
measureable ulcer. The decision over whether to treat with topical therapy or not was based on the views of 60 
the dermatologist in discussion with patients.  61 
Patients were excluded if they had pustular or granulomatous PG variants (as they may respond differently to 62 
therapy and measurement of a single ulcer was not possible); if they had received oral prednisolone, 63 
ciclosporin or intravenous immunoglobulin for the treatment of PG in the previous month, or were 64 
participating in another clinical trial.  65 
Ongoing treatment with systemic therapies for the management of underlying co-morbidities (e.g. rheumatoid 66 
arthritis) was permitted.  67 
Interventions 68 
Patients received topically applied interventions for the treatment of PG. The dermatologist was free to 69 
prescribe whichever therapy and dosage regimen they preferred according to local practice. In the UK, normal 70 
practice would be to apply topical interventions to the inflammatory edge of the ulcer. Systemic therapies for 71 
the treatment of PG were prohibited, but were continued if taken for other conditions.  72 
Assessments and outcomes 73 
Study visits took place at 2 weeks, 6 weeks and 6 months (or at time of healing if sooner).  Other unscheduled 74 
consultations took place as per normal practice. 75 
A target lesion was used for outcome assessment. Lesion size was captured by the treating dermatologist 76 
based on maximal longitudinal length and maximum perpendicular length, converted to area by the formula 77 
(length x width x 0.785), which approximates an ellipse.  78 
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Outcomes: i) speed of healing at 6 weeks (primary outcome in-line with RCT primary outcome); ii) proportion 79 
healed by 6 months; iii) time to healing; iv) global assessment of improvement at 6 weeks and final visit; v) 80 
inflammation assessment at 6 weeks and final visit7; vi) pain in the first 6 weeks (scored daily 0 to 4); vii) 81 
quality-of-life (EuroQol 5 Dimensions, 3 Levels – EQ-5D-3L8 & Dermatology Life Quality Index - DLQI9.  82 
Healing was defined as the point at which dressings were no longer required. This was reported by the 83 
participants, and a clinic visit was arranged to confirm healing as soon as possible thereafter. In cases where 84 
the date on which dressings were stopped was unavailable, healing was assumed to have taken place on the 85 
day that the ulcer was confirmed as healed by the recruiting dermatologist. Pain scores and use of dressings 86 
were collected using daily diaries.  87 
Measures taken to control bias 88 
This was an open study, with no control group. In order to mitigate the risk of bias, consecutive participants 89 
were enrolled into the study and followed up prospectively. Outcomes were assessed using standard methods 90 
and clinicians’ and patients’ views were compared where appropriate. Every effort was made to maintain 91 
follow-up of all participants. 92 
Sample size 93 
This was a pragmatic cohort study. No formal sample size calculation was performed, as this was a descriptive 94 
study without formal between-treatment comparisons. 95 
Statistical analysis 96 
The primary analysis included all participants who received at least one topical medication and had available 97 
data at both the baseline and the 6 week visit. Pre-defined sub-groups were i) participants who received 98 
clobetasol propionate 0.05%, and ii) participants who received a topical calcineurin inhibitor (tacrolimus or 99 
pimecrolimus). 100 
Data are presented descriptively and data relating to participants of the STOP GAP RCT are included alongside 101 
those of the topical therapy cohort, but no formal comparisons have been made. 102 
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If a participant received more than one topical medication, they were included in all relevant study 103 
populations. Participants who withdrew due to lack of treatment response, or who started a systemic 104 
medication during the period of the study were classed as treatment failures for the topical medication. 105 
Exploratory analyses adjusting for lesion size at baseline, presence of underlying autoimmune disease, age, 106 
weight, sex and size of recruiting centre were conducted to determine possible factors associated with 107 
treatment response. Linear regression models were used for continuous outcomes, logistic regression for 108 
binary outcomes and cox proportional hazards for time to event outcomes. 109 
Results 110 
Participants and treatment allocation 111 
Recruitment took place between July 2009 and June 2012.   112 
In total, 67 participants were enrolled in the study, but one was subsequently excluded from the analysis 113 
having received oral prednisolone for PG (Figure 1).  114 
Forty-nine (74.2%) participants received clobetasol propionate 0.05% (Dermovate™, GlaxoSmithKline); 10 115 
(15.2%) received tacrolimus 0.03% or 0.1% (Protopic®; Astellas Pharma); and eight received other topical 116 
interventions including other topical corticosteroids (n=6), fludroxycortide impregnated tape (Haelan® Tape, 117 
Typharm) (n=1), and lymecycline (Tetralysal® 300, Galderma) (n=1). One participant received both clobetasol 118 
propionate and tacrolimus and was therefore included in both sub-groups. Five participants in the clobetasol 119 
propionate group were taking concurrent anti-inflammatory/immune modifying medications for the treatment 120 
of other conditions including azathioprine (n = 2), tetracyclines (n = 2) and anti-TNF (n = 1). 121 
The reason for choosing systemic or topical therapy (and therefore eligibility for the cohort study or the RCT), 122 
were: topical treatment failure - for those opting for systemic therapy (n=47); features of the disease (n=43); 123 
and patient’s preference (n=6).  124 
Details of demographic and baseline characteristics are summarised (Table 1: Baseline characteristics of 125 
participants in STOP GAP RCT and topical therapies cohort study 126 
Table 2: Treatment response (RCT participants and observational cohort) 127 
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List of Figures 128 
Figure 1: Participant flow   129 
Figure 2: Kaplan-Meier plot of time to healing  130 
Figure 3: Global treatment response at final visit (clinician assessed)   131 
Figure 4: Global treatment response at final visit (patient assessed)  132 
 133 
). The majority of participants were identified through dermatology services (47; 71.2%); others were 134 
identified from gastroenterology (7; 10.6%), rheumatology (1; 1.5%), general medicine (2.0; 3%) and other 135 
sources (9; 13.6%).  136 
Baseline characteristics for participants in the cohort study were broadly similar to those enrolled in the 137 
parallel RCT, with the exception that the mean lesion size was smaller (4.7cm2 versus 9cm2), the mean number 138 
of ulcers was lower (1.6 versus 2.4), and fewer participants had had PG previously (18% versus 31%) (Table 1).  139 
Adherence to medication 140 
Only 12/66 (18.2%) participants provided data on adherence to their prescribed treatments at the end of the 141 
study. Nevertheless, the levels of treatment response achieved would suggest that the participants were using 142 
their medications broadly as prescribed.  Nine participants in the clobetasol propionate group used systemic 143 
medication for comorbidities during the study (azathioprine n=2; anti-TNF n=1; tetracyclines n=2). 144 
Treatment response 145 
Details of the clinical outcomes are summarised (Table 2).  146 
Mean speed of healing was -0.1 cm2 per day (SD 0.3). This is approximately half that observed in the RCT 147 
patients receiving systemic therapy, but the method of assessment was different for the two studies (physical 148 
measurements by clinician versus planimetry from digital images), and so direct comparison is difficult. The 149 
mean change from baseline in area of the lesion at the final visit was –4.2 (SD 11.5)cm2, with similar changes 150 
reported in the clobetasol and tacrolimus sub-groups (–4.0 (SD 11.9) and –3.9 (SD 6.0), respectively).   151 
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Overall, 28 (43.8%) participants healed on topical therapy alone within the 6-month study period. Twenty two 152 
(33.3%) required systemic therapy, and of these 13 (59.1%) went on to be enrolled into the RCT (Figure 1). For 153 
those that entered the RCT, 8 (61.5%) healed by 6 months, with 3 of the 13 (23.1%) healing by 6 weeks. 154 
Ulcers healed in a median duration of 145 days (95% CI: 96 days, ∞) (Table 2, Figure 2). Cox proportional 155 
hazards model suggested that size of initial lesion was an important predictive factor in determining time to 156 
healing (HR 0.94 (95% CI: 0.88, 1.00); p = 0.043). Presence of underlying autoimmune disease was not 157 
predictive (HR 0.90 (95% CI: 0.41, 1.95); p = 0.786).  158 
Global disease severity, as reported by clinicians and patients, is summarised (Figure 3, Figure 4). Self-reported 159 
pain gradually reduced during the first 6 weeks of treatment, and quality of life scores improved for both 160 
disease specific (DLQI) and general health status (EQ-5D-3L) questionnaires (Table 2). No covariates were 161 
predictive of scores at final visit for any of these outcomes, other than baseline scores for DLQI and EQ-5D VAS 162 
(DLQI estimate –0.47 (95% CI –0.77, –0.17); p = 0.003. EQ-5D VAS estimate –0.40 (95% CI: –0.65, –0.15); p = 163 
0.003). 164 
Recurrence 165 
Of the 28 participants whose ulcer had healed, 27 had recurrence data available (minimum follow-up from 166 
time of healing 5.5 months; maximum follow-up 37.2 months). Overall 4/27 (14.8%) participants had a 167 
recurrence subsequent to their initial episode. 168 
Discussion  169 
Main findings  170 
This prospective cohort study of patients receiving topical therapy for the treatment of PG suggests that many 171 
patients with limited PG can be managed effectively with topical therapy alone. For almost half of the 172 
participants, healing was achieved within the 6-month study window and most of these had healed within 2 173 
months. This is similar to the proportions healed in the STOP GAP RCT, where again roughly half of the ulcers 174 
had healed by 6 months. Care should be taken when comparing healing rates between the RCT and the cohort 175 
study as participants in the RCT had more severe disease, as demonstrated by the increased number of ulcers, 176 
larger ulcer size at baseline, and greater impact on quality of life. Of those who failed to heal on topical 177 
9 
 
 
 
therapy, one third subsequently received systemic therapy; suggesting that not all patients can be adequately 178 
treated with topical therapy alone.  179 
The most important predictor of time to healing was size of the ulcer at presentation. This is consistent with 180 
previous findings10. 181 
Given the increased mortality risk for patients with PG compared to patients with inflammatory bowel disease 182 
and apparently healthy individuals,3 it is important to evaluate the role of topical therapies for the 183 
management of PG. Similar concerns about increased mortality and morbidity in bullous pemphigoid patients 184 
(that could be partly due to systemic therapies such as prednisolone), led to an RCT by Joly et al. who found 185 
that mortality was reduced in those treated with potent topical steroids compared to those receiving systemic 186 
steroids.11  187 
The potential impact of PG on patients’ quality of life is high. Baseline EQ-5D-3L scores of 0.59 (cohort study) 188 
and 0.48 (RCT) are comparable to patients with mild to severe heart failure; where EQ-5D-3L scores of 0.78 (SD 189 
0.18) to 0.51 (SD 0.21) respectively have been reported.12 190 
One of the objectives of this study was to maintain contact with potential trial participants in order to improve 191 
recruitment into the RCT. In this regard, the cohort study was extremely effective, and resulted in an 192 
additional 13/121 (11%) patients being enrolled into the RCT. For trials of rare conditions, where the evidence 193 
base is limited, the added complexities and expense of running a parallel study of this kind can often be 194 
warranted.13  195 
Strengths and limitations 196 
This multi-centre study is much larger than any of the previously published prospective cohort studies of PG 197 
patients.4, 5, 14 Clinicians prescribed topical medication in line with local practice, but treatment allocations 198 
were not randomised. As a result, it is not possible to make formal comparison of different topical treatments 199 
such as corticosteroids versus tacrolimus. Data on sub-groups of patients are presented for interest, but 200 
should be interpreted cautiously. Tacrolimus may be an effective treatment for PG, but further evaluation in 201 
comparison to topical corticosteroids is required. Very little is known about the natural history of PG if left 202 
untreated. In the absence of placebo control arm, it is not possible to say whether or not the lesions would 203 
have healed without intervention, although clinical experience would suggest that this is unlikely. 204 
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Generalisability 205 
This was a pragmatic study that reflected current practice. For an uncommon condition such as PG it was 206 
necessary to recruit across many hospitals, which aids the generalisabilty of the results. Nevertheless, this 207 
cohort of patients was recruited alongside an RCT of systemic treatments for PG and this may have impacted 208 
on the type of patients agreeing to take part. Patients with more severe disease were randomised into the RCT 209 
and those with milder or more localised disease entered the cohort study. 210 
Clinical conclusions 211 
Mild PG may be controlled effectively using topical agents without incurring the side-effects associated with 212 
systemic treatments. The importance of ulcer size on presentation in determining treatment response, and the 213 
relatively high recurrence rates are findings that will assist clinicians in optimising the management of PG, and 214 
in managing patients’ expectations with regards to the potential effectiveness of treatments. 215 
 216 
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Table 1: Baseline characteristics of participants in STOP GAP RCT and topical therapies cohort study 
  RCT  Cohort study  Cohort sub-groups 
  n= 112 n = 66 
clobetasol 
propionate n=49 
tacrolimus 
n= 10 
Demographics 
Age: years Mean (SD) 54.4 (16.3) 57.3 (17.3) 57.5 (17.9) 53.0 (13.0) 
Sex: n (%) Female 73 (65.2) 44 (66.7) 34 (69.4) 6 (60.0) 
Ethnicity: n (%) White 108 (96.4) 64 (97.0) 47 (95.9) 10 (100.0) 
Weight: kg Mean (SD) 90.7 (25.8) 80.4 (20.3) 77.8 (17.2) 86.2 (29.7) 
Medical History 
Underlying    co-
morbidities: n (%) 
 
Crohn’s Disease 8 (7.1) 6 (9.1) 2 (4.1) 2 (20.0) 
Ulcerative colitis 15 (13.4) 8 (12.1) 7 (14.3) 1 (10.0) 
Rheumatoid 
arthritis 
8 (7.1) 2 (3.0) 2 (4.1) 0 (0.0) 
Other 
inflammatory 
arthritis 
6 (5.4) 5 (7.6) 3 (6.1) 2 (20.0) 
Monoclonal 
gammopathy 
0 (0.0) 1 (1.5) 1 (2.0) 0 (0.0) 
Myeloma 0 (0.0) 1 (1.5) 1 (2.0) 0 (0.0) 
Haematological 
malignancy 
0 (0.0) 1 (1.5) 1 (2.0) 0 (0.0) 
Other malignancy 4 (3.6) 6 (9.1) 5 (10.2) 0 (0.0) 
Diabetes 13 (11.6) 7 (10.6) 5 (10.2) 2 (20.0) 
Renal impairment 2 (1.8) 3 (4.5) 2 (4.1) 0 (0.0) 
Epilepsy 1 (0.9) 1 (1.5) 1 (2.0) 0 (0.0) 
Characteristics of PG 
Type of PG: n (%) 
 
Classical 97 (86.6) 55 (83.3) 43 (87.8) 9 (90.0) 
Cribriform 6 (5.4) 1 (1.5) 0 (0.0) 0 (0.0) 
Peristomal 4 (3.6) 6 (9.1) 3 (6.1) 1 (10.0) 
Bullous 1 (0.9) 2 (3.0) 2 (4.1) 0 (0.0) 
Unsure 4 (3.6) 2 (3.0) 1 (2.0) 0 (0.0) 
Previous episode 
of PG: 
Yes n (%) 31 (27.7) 18 (27.3) 12 (24.5) 3 (30.0) 
Area of target 
lesion: cm2 
n 112 65 48 10 
Median (Q1; Q3) 9.0 (3.2, 24.4) 4.7 (2.4; 11.0) 4.4 (1.6; 10.5) 6.8 [2.8, 11.0] 
Location of lesion: 
n (%) 
Upper limb 3 (2.7) 7 (10.6) 6 (12.2) 0 (0.0) 
Lower limb 75 67.0) 39 (59.1) 29 (59.2) 6 (60.0) 
Other 34 (30.4) 20 (30.3) 14 (28.6) 4 (40.0) 
Number of lesions 
 n=110 n = 65 (n = 48) (n=10) 
Mean (SD) 2.4 (2.1) 1.6 (1.2) 1.6 (1.1) 1.8 (1.1) 
 n 112 66 49 10 
Erytherma 
n (%) 
None 6 (5.4) 0 (0.0) 0 (0.0) 0 (0.0) 
Slight 5 (4.5) 9 (13.6) 10 (20.4) 1 (10.0) 
Moderate  36 (32.1) 10 (15.2) 15 (30.6) 8 (80.0) 
Severe 39 (34.8) 32 (48.5) 16 (32.7) 1 (10.0) 
Very Severe 26 (23.2) 15 (22.7) 8 (16.3) 0 (0.0) 
 n= 112 65 49 10 
Border Elevation 
n (%) 
None 5 (4.5) 14 (21.5) 6 (12.2) 0 (0.0) 
Slight 53 (47.3) 23 (35.4) 24 (49.0) 1 (10.0) 
Moderate  36 (32.1) 23 (35.4) 17 (34.7) 8 (80.0) 
Severe 13 (11.6) 4 (6.2) 1 (2.0) 1 (10.0) 
Very Severe 5 (4.5) 1 (1.5) 1 (2.0) 0 (0.0) 
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Exudate 
n (%) 
n= 112 66 49 10 
None 4 (3.6) 8 (12.1) 9 (18.4) 0 (0.0) 
Slight 16 (14.3) 13 (19.7) 12 (24.5) 1 (10.0) 
Moderate  59 (52.7) 27 (40.9) 22 (44.9) 8 (80.0) 
Severe 15 (13.4) 11 (16.7) 4 (8.2) 1 (10.0) 
Very Severe 18 (16.1) 7 (10.6) 2 (4.1) 0 (0.0) 
 
 
Table 2: Treatment response (RCT participants and cohort participants) 
   Sub-groups  
 RCT participants 
n=112 
All cohort participants 
n = 66 
clobetasol propionate 
n=49 
tacrolimus 
n= 10 
Speed of healing n= 108 n = 54 n = 37 n = 10 
Mean (SD) cm2/day -0.2 (0.8) -0.1 (0.3) -0.1 (0.2)  -0.1 (0.1)  
% healed by final visit  
(up to 6 months) 
n=112 n=64 n=47 n= 10 
n (%) 53 (47.3) 28 (43.8) 20 (42.6) 5 (50.0)  
Time to healing (days) n=112 n=64 n=47 n= 10 
Median (95% CI) 169 days (113; ∞) 145 days (96; ∞) 136 days (46; ∞) 161 days (13; ∞) 
Area of lesion: cm2 * n = 108 n=55 n=38 n= 10 
Baseline: median (Q1; Q3) 9.0 (3.2; 24.8) 5.9 (1.8; 13.6) 6.4 (1.6; 14.0) 6.8 (2.8; 11.0)  
Final visit: median (Q1; Q3) 0.0 (0.0; 8.1) 0.0 (0.0; 9.0)  0.0 (0.0; 9.0) 1.2 (0.0; 3.5)  
Mean change from baseline at final visit (SD) -9.1 (51.1) -4.2 (11.5) -4.0 (11.9) -3.9 (6.0)  
Median change (Q1; Q3) -5.0 (-15.8; -1.5) -3.4 (-8.7; -0.3) -1.7 (-7.4; -0.2) -3.3 (-8.5; -0.3) 
Resolution of inflammation#  n=107 n=54 n=49 n= 10 
6 weeks: n (%) 11 (10.3) 8 (14.8) 6 (16.2)  0 (0.0)  
 n= 108 n=55 n=38 n=10 
Final visit: n (%) 20 (18.5) 12 (21.8) 10 (26.3) 1 (10.0)  
AUC for weekly pain in 1st six weeks (range 0 to 20); 
high score = worse 
n=77 n=37 n=24 n= 7 
Mean (SD) 7.6 (5.2) 5.4 (5.2) 5.6 (5.2) 7.3 (6.3) 
DLQI (range 0 to 30); high score = worse n = 111 n=66 n=49 n= 10 
Baseline: mean (SD) 11.7 (8.2) 8.4 (6.0)  8.5 (6.0) 8.8 (4.6) 
 n = 66 n=49 n=32 n= 10 
Final visit: mean (SD) 5.5 (7.2) 6.2 (6.8) 7.6 (7.5) 4.6 (5.4) 
EQ-5D* (range 0 to 1); high score = better n=108 n= 66 n= 49 n= 10 
Baseline: mean (SD) 0.48 (0.4) 0.59 (0.3) 0.60 (0.3) 0.51 (0.3) 
 n = 69 n= 51 n= 34 n= 10 
Final visit: mean (SD) 0.71 (0.4) 0.69 (0.3) 0.65 (0.3) 0.73 (0.3) 
EQ-5D VAS (range 0 to 100); high score = better n =110 n= 66 n= 49 n= 10 
Baseline: mean (SD) 62.0 (21.8) 67.0 (20.4) 65.6 (21.9) 64.4 (15.9) 
: n = 70 n= 50 n= 33 n= 10 
Final visit: mean (SD) 72.1 (21.2) 73.6 (20.5) 69.3 (22.2) 78.2 (13.1) 
Recurrence (in those who had healed by 6 months)$ n=52 n=27 n=19 n= 5 
n (%) 15 (28.8) 4 (14.8) 4 (21.1) 0 (0.0)  
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# Assessed by clinician, resolution of inflammation defined as erythema and border elevation reduced to 
“none” – as per Foss 7. $ Minimum follow-up after healing: RCT (0 to 40.3 months); cohort (5.5 months to 
37.2), depending on when recruited. * Captures health utility based on responses (0 to 2) for mobility, self-
care, usual activities, pain/discomfort, anxiety/depression. 
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